Nuvation Bio Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
NUVB New York 2836 www.nuvationbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Nuvation Bio Inc.

Down 24% in 4 Weeks, Here's Why Nuvation Bio (NUVB) Looks Ripe for a Turnaround - Jan 13th, 2026 7:35 am
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference - Jan 12th, 2026 6:00 am
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan - Jan 12th, 2026 5:30 am
Nuvation Bio Inc.'s (NYSE:NUVB) institutional investors lost 5.2% last week but have benefitted from longer-term gains - Jan 7th, 2026 5:16 am
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 6th, 2026 2:05 pm
Wall Street Analysts Think Nuvation Bio (NUVB) Could Surge 32.05%: Read This Before Placing a Bet - Jan 5th, 2026 7:55 am
Wall Street Analysts Believe Nuvation Bio (NUVB) Could Rally 25.14%: Here's is How to Trade - Dec 19th, 2025 7:55 am
Has Nuvation Bio’s 234% Surge in 2025 Already Reflected Its Growth Potential? - Dec 17th, 2025 6:07 am
Nuvation Bio (NUVB): Reassessing Valuation After a 78% Monthly Surge in the Share Price - Dec 16th, 2025 7:06 pm
Nuvation Bio (NUVB) Upgraded to Buy: Here's What You Should Know - Dec 15th, 2025 10:00 am
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List - Dec 6th, 2025 8:40 pm
Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result - Dec 4th, 2025 10:55 am
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology - Dec 3rd, 2025 6:00 am
Top Growth Companies With Strong Insider Ownership November 2025 - Nov 28th, 2025 10:35 am
Nuvation Bio (NUVB) Halts NUV-1511 and Highlights Safusidenib Data Is Strategic Focus Shifting? - Nov 28th, 2025 4:14 am
Nuvation Bio (NUVB): Exploring Valuation After a 52% One-Month Rally - Nov 27th, 2025 8:11 pm
Nuvation Bio to Participate in Upcoming Investor Conferences - Nov 26th, 2025 2:05 pm
Nuvation Bio (NUVB) Jumps to 3-Year High on Bullish Coverage - Nov 20th, 2025 4:27 am
Nuvation Bio Shares Have Room to Run on Ibtrozi Momentum, Wedbush Says - Nov 19th, 2025 1:25 pm
Nuvation Bio Inc. (NUVB) is a Buy at H.C. Wainwright on Cancer Drug Development Progress - Nov 18th, 2025 4:17 am